Effectiveness of antiretroviral therapy in HIV-1-infected active drug users attended in a drug abuse outpatient treatment facility providing a multidisciplinary care strategy

Current HIV Research

Volumn 10, Issue 4, 2012, Pages 356-363

  Sánchez, Gabriel V ^a   Llibre, Josep M ^a,b,c   Torrens, Marta ^a   Sanvisens, Arantza ^a,c   Mateu, Gerard ^a   Knobel, Hernando ^a   Langohr, Klaus ^d,e   Santos, Jose R ^a,b,c   Muga, Roberto ^a,c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Lluita Contra la SIDA Foundation   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^e HOSPITAL DEL MAR   (Spain)

Author keywords

Active drug users; Antiretroviral effectiveness; HAART; Multidisciplinary care; Treatment adherence

Indexed keywords

ABACAVIR; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; LAMIVUDINE; METHADONE; MOOD STABILIZER; NEUROLEPTIC AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG TREATMENT FAILURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PSYCHOSOCIAL CARE; SEXUAL TRANSMISSION; TREATMENT REFUSAL; TREATMENT RESPONSE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COMORBIDITY; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; METHADONE; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; PATIENT SELECTION; QUESTIONNAIRES; RNA, VIRAL; SEXUAL BEHAVIOR; SPAIN; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84862590561     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212800792504     Document Type: Article

References (43)

1. Lert F, Kazatchkine MD. Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. Int J Drug Policy 2007; 18: 255-61.
2. Wood E, Kerr T, Tyndall MW, Montaner JS. A review of barriers and facilitators of HIV treatment among injection drug users. AIDS 2008; 22(11): 1247-56.
3. Celentano DD, Lucas G. Optimizing treatment outcomes in HIV-infected patients with substance abuse issues. Clin Infect Dis 2007; 45 Suppl 4: S318-23.
4. Mehta SH, Kirk GD, Astemborski J, Galai N, Celentano DD. Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996-2008. Clin Infect Dis 2010; 50(12): 1664-71.
5. Pérez-Hoyos S, del Amo J, Muga R, et al. GEMES (Spanish Multicenter Study Group of Seroconverters). Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 2003; 17: 353-9.
6. Willenbring ML. Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches. AIDS 2005; Suppl 3: S227-37.
7. Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction 2004; 99: 361-8.
8. Wood E, Hogg RS, Kerr T, Palepu A, Zhang R, Montaner JS. Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naive HIV-infected injection drug users. AIDS 2005; 19: 837-9.
9. Roux P, Carrieri MP, Villes V, et al. MANIF 2000 cohort study group. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction 2008; 103: 1828-36.
10. Roux P, Carrieri MP, Cohen J, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis 2009; 49: 1433-40.
11. Conway B, Prasad J, Reynolds R, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis 2004; 38 Suppl 5: S402-8.
12. Clarke S, Keenan E, Ryan M, Barry M, Mulcahy F. Directly observed antiretroviral therapy for injection drug users with HIV infection. AIDS Read 2002; 12: 305-7, 312-6.
13. Lucas GM, Weidle PJ, Hader S, Moore RD. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clin Infect Dis 2004; 38: S409-13.
14. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis 2006; 42: 1628-35.
15. Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over selfadministered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis 2007; 45: 770-8.
16. Sullivan LE, Bruce RD, Haltiwanger D, et al. Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis 2006; 43: S191-6.
17. Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis 2006; 43: S184-90.
18. Weaver MR, Conover CJ, Proescholdbell RJ, et al. Costeffectiveness analysis of integrated care people with HIV, chronic mental illness and substance abuse disorders. J Ment Health Policy Econ 2009; 12: 33-46.
19. American Psychiatric Association: Practice Guidelines. Available at: http://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx. Accessed may 5, 2011.
20. Astals M, Díaz L, Domingo-Salvany A, Martín-Santos R, Bulbena A, Torrens M. Impact of co-occurring psychiatric disorders on retention in a methadone maintenance program: an 18-month follow-up study Int J Environ Res Public Health 2009; 6: 2822-32.
21. Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2011). Available at: http://www.gesida.seimc.org/index.asp. Accessed May 5, 2011.
22. Rodríguez-Arenas MA, Jarrín I, del Amo J, et al. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses 2006; 22: 715-23.
23. Lucas GM, Mullen BA, McCaul ME, Weidle PJ, Hader S, Moore RD. Adherence, drug use, and treatment failure in a methadoneclinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STDS 2007; 8: 564-74.
24. Raffa JD, Grebely J, Tossonian H, et al. The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program. Drug Alcohol Depend 2007; 89: 306-9.
25. Maru DS, Kozal MJ, Bruce RD, Springer SA, Altice FL. Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trial. J Acquir Immune Defic Syndr 2007; 46: 555-63.
26. Werb D, Mills EJ, Montaner JS, Wood E. Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis. Lancet Infect Dis 2010; 10(7): 464-9.
27. Maru DS, Bruce RD, Walton M, Springer SA, Altice FL. Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial. J Acquir Immune Defic Syndr 2009; 50: 176-81.
28. Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction 2008; 103: 1242-57.
29. Lok JJ, Bosch RJ, Benson CA, Collier AC, Robbins GK, Shafer RW, Hughes MD; ALLRT team. Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS 2010; 24: 1867-76.
30. Buchacz K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, Novak RM, Wood KC, Brooks JT; HOPS Investigators. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 2010; 24: 1549-59.
31. Dronda F, Zamora J, Moreno S, et al.CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use. AIDS 2004; 18: 2210-2.
32. Antonucci G, Girardi E, Cozzi-Lepri A, et al. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Clin Infect Dis 2005; 40: 101-9.
33. Maru DS, Bruce RD, Walton M, Mezger JA, Springer SA, Shield D, Altice FL. Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Behav 2008; 12: 284-93.
34. Macalino GE, Hogan JW, Mitty JA, et al. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS 2007; 21: 1473-7.
35. Smith-Rohrberg D, Mezger J, Walton M, Bruce RD, Altice FL. Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users J Acquir Immune Defic Syndr 2006; 43: S48-53.
36. Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care 2009; 21: 976-83.
37. Delgado J, Heath KV, Yip B, et al. Highly active antiretroviral therapy: physician experience and enhanced adherence to prescription refill. Antivir Ther 2003; 8: 471-8.
38. McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis 2005; 41: S89-95.
39. Tossonian HK, Raffa JD, Grebely J, et al. Methadone dosing strategies in HIV-infected injection drug users enrolled in a directly observed therapy program. J Acquir Immune Defic Syndr 2007; 45: 324-7.
40. Johnson MO, Chesney MA, Goldstein RB, et al; NIMH Healthy Living Project Team. Positive provider interactions, adherence self-efficacy, and adherence to antiretroviral medications among HIV-infected adults: A mediation model. AIDS Patient Care STDS 2006; 20: 258-68.
41. Bakken S, Holzemer WL, Brown MA, et al. Relationships between perception of engagement with health care provider and demographic characteristics, health status, and adherence to therapeutic regimen in persons with HIV/AIDS. AIDS Patient Care STDS 2000; 14: 189-97.
42. Parsons JT, Rosof E, Punzalan JC, Di Maria L. Integration of motivational interviewing and cognitive behavioral therapy to improve HIV medication adherence and reduce substance use among HIV-positive men and women: results of a pilot project. AIDS Patient Care STDS 2005; 19: 31-9.
43. Parsons JT, Golub SA, Rosof E, Holder C. Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial. J Acquir Immune Defic Syndr 2007; 46: 443-50.